IP Library Granted Patent US 7,763,460
Granted Patent B2
US 7,763,460 · App. 11/296,571 · Granted Jul 27, 2010

Methods and compositions for detecting herpes simplex virus type 2

Assignee: Focus Diagnostics, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,763,460
App. No.
11/296,571
Granted
Jul 27, 2010
Kind
B2
Abstract

The invention provides methods for sensitive and specific detection of anti-HSV-2 antibodies by depletion of cross-reactive (non-specific) antibodies in a biological sample that can lead to a false positive result. The invention also features compositions, including nucleic acids, polypeptides, and kits, for use in the methods of the invention.

Claims (43)

1. A method of detecting the presence or absence of a specific anti-herpes simplex virus type-2 (HSV-2) antibody in a biological sample, comprising:

(a) contacting a biological sample suspected of containing anti-HSV-2 antibodies with a first antigen comprising the amino acid sequence GHTNTSSAS (SEQ ID NO:07), wherein said first antigen is not a full length glycoprotein G2 (gG2) polypeptide,

(b) contacting said biological sample with a second antigen capable of binding said specific anti-HSV-2 antibody, and

(c) detecting the presence or absence of specific anti-HSV-2 antibody in said biological sample wherein said specific anti-HSV-2 antibody detected in said sample is bound to said second antigen,

wherein said first antigen is not reactive with said specific anti-HSV-2 antibody.

2. The method of claim 1 , wherein said first antigen is J24, JA, JA1, or JA2.

3. The method of claim 1 , wherein step (a) further comprises contacting said biological sample with a third antigen comprising the amino acid sequence AAKTPPTTPAP (SEQ ID NO:06), wherein said third antigen is not a full length glycoprotein G2 (gG2) polypeptide, wherein said third antigen is not reactive with said specific anti-HSV-2 antibody.

4. The method of claim 1 , wherein said first antigen comprises a polypeptide having an amino acid sequence consisting essentially of GHTNTSSAS (SEQ ID NO:07).

5. The method of claim 1 , wherein said detecting further comprises contacting said sample with one or more detectably labeled anti-human immunoglobulin antibodies.

6. The method of claim 1 , wherein at least one of said antigens is immobilized on a nitrocellulose membrane support.

7. The method of claim 1 , wherein at least one of said antigens is immobilized on a solid support.

8. The method of claim 7 , wherein said solid support is selected from the group consisting of a microparticle, an agarose bead, and a magnetic bead.

9. The method of claim 1 , wherein said first antigen is not immobilized on a solid support and said second antigen is immobilized on a solid support.

10. The method of claim 1 , wherein said first antigen is immobilized on a first solid support, and said second antigen is immobilized on a second solid support.

11. The method of claim 1 , wherein said antibodies bound to said first antigen are removed from the sample prior to step (c).

12. The method of claim 1 , wherein said antibodies bound to said first antigen are removed from the sample prior to step (b).

13. The method of claim 1 , wherein said first antigen is detectably labeled.

14. The method of claim 1 , wherein said second antigen is a glycoprotein selected from the group consisting of: gC2, gG2, gB2, gD2 and fragments thereof.

15. The method of claim 1 , wherein said second antigen comprises an epitope from the glycoprotein, gG2.

16. The method of claim 1 , wherein said second antigen is the full-length glycoprotein gG2.

17. The method of claim 1 , wherein said second antigen comprises a first gG2Δ polypeptide, wherein said first gG2Δ polypeptide lacks the amino acid sequence of GHTNTSSAS (SEQ ID NO:07).

18. The method of claim 17 , wherein said first gG2Δ polypeptide comprises the amino acid sequence of SEQ ID NO:10.

19. The method of claim 17 , wherein said first gG2Δ polypeptide is selected from the group consisting of: gG2ΔJ24, gG2ΔJA, gG2ΔJA1, and gG2ΔJA2.

20. The method of claim 17 , wherein said first gG2Δ polypeptide comprises a substitution at the position corresponding to the amino acid sequence of SEQ ID NO:07, wherein said first gG2Δ polypeptide is selected from the group consisting of: gG2subJ24, gG2subJA, gG2subJA1, and gG2subJA2.

21. The method of claim 17 , wherein said first gG2Δ polypeptide comprises a substitution of about nine glycine residues at the position corresponding to the amino acid sequence of SEQ ID NO:07 in the native polypeptide.

22. The method of claim 1 , wherein said second antigen comprises a second gG2Δ polypeptide, wherein said second gG2Δ polypeptide lacks the amino acid sequence of AAKTPPTTPAP (SEQ ID NO:06).

23. The method of claim 22 , wherein said second gG2Δ polypeptide comprises the amino acid sequence of SEQ ID NO:12.

24. The method of claim 22 , wherein said second gG2Δ polypeptide is selected from the group consisting of: gG2ΔJ24, gG2ΔJA, and gG2ΔJA2.

25. The method of claim 22 , wherein said second gG2Δ polypeptide comprises a substitution at the position corresponding to the amino acid sequence of SEQ ID NO: 06, wherein said second gG2Δ polypeptide is selected from the group consisting of: gG2subJ24, gG2subJA, and gG2subJA2.

26. The method of claim 22 , wherein said second gG2Δ polypeptide comprises a substitution of about eleven glycine residues at the position corresponding to the amino acid sequence of SEQ ID NO:06 in the native polypeptide.

27. The method of claim 3 , wherein said third antigen is the amino acid sequence AAKTPPTTPAP (SEQ ID NO:06).

28. The method of claim 3 , wherein said third antigen comprises a polypeptide having an amino acid sequence comprising AAKTPPTTPAP (SEQ ID NO:06).

29. The method of claim 3 , wherein said second antigen is the full-length glycoprotein, gG2 and said third antigen comprises a polypeptide having an amino acid sequence comprising AAKTPPTTPAP (SEQ ID NO:06).

30. The method of claim 3 , wherein at least one of said antigens is immobilized on a nitrocellulose membrane support.

31. The method of claim 3 , wherein at least one of said antigens is immobilized on a solid support.

32. The method of claim 3 , wherein said solid support is selected from the group consisting of: a microparticle, an agarose bead, and a magnetic bead.

33. The method of claim 3 , wherein said first and said third antigens are not immobilized on a solid support and said second antigen is immobilized on a solid support.

34. The method of claim 3 , wherein at least one of said first and said third antigens is immobilized on a first solid support, and said second antigen is immobilized on a second solid support.

35. The method of claim 3 , wherein said antibodies bound to said first and said third antigens are removed from the sample prior to said detecting step.

36. The method of claim 3 , wherein said antibodies bound to said first and said third antigens are removed from the sample prior to contacting the sample with said second antigen.

37. The method of claim 3 , wherein at least one of said first and said third antigens is detectably labeled.

38. The method of claim 3 , wherein at least one of said first and said third antigens is a fusion protein.

39. The method of claim 4 , wherein said first antigen comprises a polypeptide having an amino acid sequence consisting of GHTNTSSAS (SEQ ID NO:07).

Assignments (2)
CHANGE OF NAME Recorded Sep 11, 2017
From: FOCUS DIAGNOSTICS, INC.
To: QUEST DIAGNOSTICS INFECTIOUS DISEASE, INC.
Reel/Frame 043811/0131 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 13, 2006
From: SU, XIN; KONG, LILLY; HOGREFE, WAYNE
To: FOCUS DIAGNOSTICS, INC.
Reel/Frame 017466/0173 →
Continuity (2)
Provisional Application 6069363200 · Jun 24, 2005
Related Publication 20060292557A1 · Dec 28, 2006